Findings presented will highlight novel correlates of severity and protection during respiratory illness, including SARS-CoV-2 infection, that could be useful as biomarkers for viral illness outcome. The session will explore new aspects of the host pathogen interface that could be harnessed as a clinical tool and lead to host-targeted therapeutics. What biomarkers can be used to determine individuals at higher risk of severe illness outcome from respiratory viral infection?
• Better understand and incorporate current and novel biomarkers for respiratory infection correlates of protection or severity, including SARS-CoV-2, into current practice
• Gain knowledge of novel techniques for tracking pathogen-host interactions over the course of infection, including single cell approaches and cell-free analyses
• Discuss comprehensive cohort study design that includes molecular, genetic, environmental, and epidemiological variables as components of immune modeling for host pathogenesis
Angela Rogers, MD, MPH, ATSF
Aubree Gordon, PhD
Emma Allen, PhD
David Boyd, PhD
Introduction
SARS-CoV-2 Repeat Infections and Breakthroughs: Correlates of Immunity and Determinants of Severity - Presentation withheld at the speaker's request
Immunology in Context
Profiling the Mucosal TCR Repertoire Landscape During Severe Pneumonia
Severe Respiratory Viral Infection Results in Persistent Immune Activation of Lung Fibroblasts Associated with Prolonged Respiratory Distress